# reload+after+2024-01-23 08:47:50.748071
address1§499 Illinois Street
address2§Suite 500
city§San Francisco
state§CA
zip§94158
country§United States
phone§415 906 4324
website§https://www.vir.bio
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
fullTimeEmployees§576
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Ann M. Hanly Ph.D.', 'age': 53, 'title': 'Executive VP & Chief Technology Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 842232, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Phillip  Pang M.D., Ph.D.', 'age': 48, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 837380, 'exercisedValue': 38475, 'unexercisedValue': 3344398}, {'maxAge': 1, 'name': 'Dr. Marianne  De Backer M.B.A., M.Sc., Ph.D.', 'age': 54, 'title': 'CEO & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Klaus  Frueh Ph.D.', 'age': 63, 'title': 'Co-Founder & Scientific Advisor', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 177661, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lawrence  Corey M.D.', 'age': 76, 'title': 'Co-Founder & Scientific Advisor', 'yearBorn': 1947, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Louis J. Picker M.D.', 'title': 'Co-Founder & Scientific Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Sung H. Lee', 'age': 53, 'title': 'Executive VP & CFO', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jennifer Eileen Towne Ph.D.', 'title': 'Executive VP & Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Heather Rowe Armstrong', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Vanina De Verneuil J.D.', 'title': 'Executive VP, General Counsel & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§4
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.386
priceToSalesTrailing12Months§11.356999
currency§USD
dateShortInterest§1702598400
forwardEps§-4.31
pegRatio§-0.3
exchange§NMS
quoteType§EQUITY
shortName§Vir Biotechnology, Inc.
longName§Vir Biotechnology, Inc.
firstTradeDateEpochUtc§1570800600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ebff203c-69dd-36be-a47c-35beb1571fec
gmtOffSetMilliseconds§-18000000
targetHighPrice§95.0
targetLowPrice§12.0
targetMeanPrice§29.5
targetMedianPrice§22.5
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§10.326
grossMargins§-2.8038101
ebitdaMargins§0.0
trailingPegRatio§None
